Cannabidiol in Gliomas: Therapeutic Potential and Nanocarrier Strategies, with an Emphasis on Vesicular Delivery Systems
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c00853 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Jagoda Szkudlarek und 2 weiteren Autor:innen. Beteiligte Einrichtung: Chair and Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 3 Rokietnicka, Poznań 60-806, Poland. Hauptthemen laut MEDLINE: Cannabidiol, Nanoparticles, Drug Delivery Systems, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for the Development of Poznan University of Medical Sciences (PUMS), Medical Research Agency, Poznan University of Medical Sciences (PUMS) through the NanoPOLIP Research Group.
Abstract (Originalsprache)
Cannabidiol (CBD), a nonpsychoactive phytocannabinoid extracted from Cannabis sativa, has emerged as a compound of considerable therapeutic interest across numerous medical disciplines, including pain management, anti-inflammatory therapy, and oncology. This review critically examines the potential of CBD in the treatment of glioblastoma multiforme (GBM), one of the most aggressive and treatment-resistant primary brain tumors. Particular emphasis is placed on the molecular mechanisms underlying CBD's antitumor activity, including the modulation of key signaling pathways, inhibition of tumor proliferation, and enhancement of chemosensitivity. Furthermore, the review highlights the increasing role of nanotechnology in overcoming the intrinsic pharmacokinetic limitations of CBD, particularly its low oral bioavailability, which presents a significant challenge to its clinical application. Advanced nanocarrier platforms, including nanoemulsions, nanoparticles, nanoparticle-based transdermal systems, nanocapsules, and liposomes, have shown promise in optimizing CBD delivery to the central nervous system (CNS). Notably, the integration of CBD into lipid-based drug delivery systems (LBDDS) is highlighted as a particularly promising strategy to potentiate its therapeutic efficacy. This approach enhances bioavailability and may amplify synergistic effects when combined with conventional chemotherapeutics or targeted agents. Overall, the synergistic use of nanotechnological approaches and CBD-based therapies may open new avenues for research, offering the potential to significantly advance treatment efficacy in glioblastoma and other diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chair and Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 3 Rokietnicka, Poznań 60-806, Poland.
- Doctoral School, Poznan University of Medical Sciences, Bukowska 70, Poznań 60-812, Poland.
ORCID-Profile: Jagoda Szkudlarek
Förderung
- Foundation for the Development of Poznan University of Medical Sciences (PUMS)
- Medical Research Agency
- Poznan University of Medical Sciences (PUMS) through the NanoPOLIP Research Group
Zitieren
APA
Szkudlarek, J., Piwowarczyk, L., & Jelińska, A. (2026). Cannabidiol in Gliomas: Therapeutic Potential and Nanocarrier Strategies, with an Emphasis on Vesicular Delivery Systems. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00853
Vancouver
Szkudlarek J, Piwowarczyk L, Jelińska A. Cannabidiol in Gliomas: Therapeutic Potential and Nanocarrier Strategies, with an Emphasis on Vesicular Delivery Systems. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c00853
BibTeX
@article{Szkudlarek2026,
author = {Szkudlarek, Jagoda and Piwowarczyk, Ludwika and Jelińska, Anna},
title = {Cannabidiol in Gliomas: Therapeutic Potential and Nanocarrier Strategies, with an Emphasis on Vesicular Delivery Systems},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c00853}
}
EUVIMED